Craneware plc Grant of Options (7265J)

TIDMCRW

RNS Number : 7265J

Craneware plc

13 September 2016

Craneware plc

("Craneware", "the Group" or the "Company")

Grant of Options

13 September 2016 - The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces that on 12 September 2016, the Remuneration Committee approved the granting of share options to certain Directors to subscribe for ordinary shares of 1p each in the Company as follows:

 
 Director         No. of options           Percentage of 
                         granted    issued share capital 
 Keith Neilson 
  (CEO)                   28,628                    0.14 
 
 

The above options have been granted at an exercise price of 1177.5p per share (being the closing market price on 12 September 2016). These options will be subject to performance criteria, such that they vest in three equal tranches over three years. One third of the share options will vest on or after 30 June 2017, one third on or after 30 June 2018 and the final third on or after 30 June 2019. The share options will not become exercisable until three years from the date of the grant.

For further information, please contact:

 
 Craneware plc    Peel Hunt          Alma 
 [phone]   [phone]     [phone] 
  3100             8900               4218 
 Keith Neilson,   Dan Webster        Caroline Forde       , 
  CEO 
 Craig Preston,   Adrian Trimmings   Hilary Buchanan 
  CFO              George Sellar      Robyn McConnachie 
 
 

About Craneware

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

Craneware is the leader in automated value cycle solutions that help US provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston and Phoenix employing over 200 staff. Craneware's market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEADNDFLLKEFF

(END) Dow Jones Newswires

September 13, 2016 09:48 ET (13:48 GMT)